GlobeNewswire: Beyond Air™ Contains the last 10 of 214 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:44:06ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/20/2849409/0/en/Beyond-Air-Announces-Pricing-of-16-0-Million-Registered-Direct-Offering-of-Common-Stock-and-Warrants.html?f=22&fvtc=4&fvtv=31360Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants2024-03-20T13:00:00Z<![CDATA[GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that it has entered into a securities purchase agreement with healthcare focused institutional investors and accredited investors, including certain directors and officers of the Company, whereby the investors have agreed to purchase 9,638,556 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,638,556 shares of common stock at a purchase price of $1.66 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $2.25 per share, will be exercisable immediately upon issuance and will have a term of three years following the date of issuance. The Company can call the warrants if it reports equal to or greater than $4.5 million of net sales for the quarter ending March 31, 2025 which will require exercise within 10 business days. The closing of the offering is expected to occur on or about March 22, 2024, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2024/02/12/2827860/0/en/Beyond-Air-Reports-Financial-Results-for-Third-Quarter-of-Fiscal-Year-2024.html?f=22&fvtc=4&fvtv=31360Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 20242024-02-12T21:05:00Z<![CDATA[Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand]]>https://www.globenewswire.com/news-release/2024/01/18/2811468/0/en/Beyond-Air-Schedules-Third-Fiscal-Quarter-2024-Financial-Results-Conference-Call-and-Webcast.html?f=22&fvtc=4&fvtv=31360Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast2024-01-18T13:00:00Z<![CDATA[Call scheduled for Monday, February 12th at 4:30 pm Eastern Time Call scheduled for Monday, February 12th at 4:30 pm Eastern Time]]>https://www.globenewswire.com/news-release/2023/12/27/2801322/0/en/Beyond-Cancer-Phase-1-Study-Clears-Cohort-1-in-Patients-with-Advanced-Relapsed-or-Refractory-Unresectable-Primary-or-Metastatic-Cutaneous-or-Subcutaneous-Solid-Tumors.html?f=22&fvtc=4&fvtv=31360Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors2023-12-27T12:30:00Z<![CDATA[No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM)]]>https://www.globenewswire.com/news-release/2023/11/15/2781400/0/en/Beyond-Air-To-Participate-in-the-35th-Annual-Piper-Sandler-Healthcare-Conference.html?f=22&fvtc=4&fvtv=31360Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference2023-11-15T21:05:00Z<![CDATA[GARDEN CITY, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in a fireside discussion and one-on-one meetings at the Piper Sandler Healthcare Conference being held November 28-30, 2023 in New York City.]]>https://www.globenewswire.com/news-release/2023/11/13/2779436/0/en/Beyond-Air-Reports-Financial-Results-for-Second-Quarter-of-Fiscal-Year-2024.html?f=22&fvtc=4&fvtv=31360Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 20242023-11-13T21:05:00Z<![CDATA[Provides fiscal year 2025 revenue guidance of $12 - $16 million]]>https://www.globenewswire.com/news-release/2023/11/03/2773315/0/en/Beyond-Cancer-Presents-Positive-First-in-Human-Clinical-Data-for-Ultra-High-Concentration-Nitric-Oxide-UNO-Therapy-in-Solid-Tumors-During-the-Society-for-Immunotherapy-of-Cancer-SI.html?f=22&fvtc=4&fvtv=31360Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting2023-11-03T16:00:00Z<![CDATA[First-in-human Phase 1 study demonstrates early clinical proof of concept]]>https://www.globenewswire.com/news-release/2023/10/19/2763669/0/en/Beyond-Air-Schedules-Second-Fiscal-Quarter-2024-Financial-Results-Conference-Call-and-Webcast.html?f=22&fvtc=4&fvtv=31360Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast2023-10-19T20:05:00Z<![CDATA[Call scheduled for Monday, November 13th at 4:30 pm Eastern Time Call scheduled for Monday, November 13th at 4:30 pm Eastern Time]]>https://www.globenewswire.com/news-release/2023/10/17/2761908/0/en/Beyond-Air-To-Participate-in-the-Truist-Securities-BioPharma-Symposium.html?f=22&fvtc=4&fvtv=31360Beyond Air® To Participate in the Truist Securities BioPharma Symposium2023-10-17T20:05:00Z<![CDATA[GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will provide a corporate presentation and participate in one-on-one meetings at the Truist Securities BioPharma Symposium being held on Wednesday, November 8, 2023 in New York, NY.]]>https://www.globenewswire.com/news-release/2023/10/17/2761389/0/en/Beyond-Cancer-Publishes-Pre-Clinical-Data-in-Cells-Demonstrating-that-the-Combination-of-Ultra-High-Concentration-Nitric-Oxide-UNO-and-Anti-mPD-1-Therapy-Improves-Tumor-Regression-.html?f=22&fvtc=4&fvtv=31360Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice2023-10-17T11:30:00Z<![CDATA[UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic response that overcomes anti-PD-1 resistance]]>PD-L1 Upregulation in CT26 and 4T1 Cells after In Vitro Exposure to UNOFigure 1T-cell profiling in tumors of CT26 mice treated with UNOFigure 2Myeloid cell profiling in CT26 tumors treated with UNOFigure 3